Caption Management’s Soleno Therapeutics SLNO Stock Holding History

Caption Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-420,143	Closed	-$14.1M	–	2011
2026 Q1	$14.1M	Buy	420,143 +378,043	+898%	+$14.8M	0.08%	262
2025 Q4	$1.95M	Sell	42,100 -327,900	-89%	-$18M	0.01%	844
2025 Q3	$25M	Buy	370,000 +106,713	+41%	+$7.91M	0.2%	109
2025 Q2	$22.1M	Sell	263,287 -31,713	-11%	-$2.37M	0.24%	82
2025 Q1	$21.1M	Buy	295,000 +271,852	+1,174%	+$13.2M	0.2%	90
2024 Q4	$1.04M	Sell	23,148 -32,052	-58%	-$1.66M	0.01%	900
2024 Q3	$2.79M	Sell	55,200 -28,526	-34%	-$1.37M	0.04%	460
2024 Q2	$3.42M	Buy	83,726 +43,726	+109%	+$1.85M	0.05%	368
2024 Q1	$1.71M	Buy	+40,000	New	+$1.81M	0.03%	581

Caption Management's SLNO Position: Q2 2026 in Review

Caption Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 420,143 shares — an estimated $14.1M sold.

Caption Management first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $25M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Caption Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Caption Management sold 420,143 Soleno Therapeutics shares in Q2 2026, an estimated $14.1M.
Caption Management first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
Caption Management's Soleno Therapeutics position peaked at $25M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.